Esophageal adenocarcinoma (EAC) is a malignancy with rising incidence in Western countries, largely due to increasing rates of gastroesophageal reflux disease and obesity. Despite advancements in treatment, the prognosis for EAC remains poor, with a five-year survival rate of less than 20% for advanced stages. Current management of locally advanced, resectable EAC often involves neoadjuvant …
